Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said it has filed two international patent applications under the Patent Cooperation Treaty (PCT) to protect its non-hallucinogenic novel non-tryptamine compounds, known as 'Family 6'.
Mindset said the filings are based on pre-clinical studies and provide it with preliminary freedom to operate for all claimed drug candidates from Family 6.
The company said it believes that its innovative drug discovery and development platform for novel psychedelic-inspired non-hallucinogenic drug candidates may have the potential to treat a wider patient population, including fragile population groups such as children or geriatric patients. It aims to reduce or remove the psychedelic effect, making in-clinic supervision unnecessary, and improving the convenience and cost of these treatment options.
“The pre-clinical study results underpinning the candidates identified in these patent applications are highly promising,” said James Lanthier, CEO of Mindset in a statement.
He added that the company’s work on these novel non-tryptamine candidates, which included in-vitro screening and in vivo studies, indicates 5-HT2A serotonin receptor activation without the in vivo signs of a hallucinogenic effect.
“While some Family 6 compounds are functionally more potent than psilocybin and 5-MeO-DMT as 5-HT2A agonists, these drug candidates elicited only a modest or no head twitch response, suggesting a non-hallucinogenic effect profile,” Lanthier explained.
Mindset aims to create optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. The company is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybins in addition to its own proprietary compounds.
The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, covering multiple drug development programs.
“We look forward to sharing future progress on our non-hallucinogenic psychedelic-inspired compounds,” concluded Lanthier.
Contact the author at jon.hopkins@proactiveinvestors.com